A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00970580

Enrollment

Registered

2009-09-02

Start date

2009-10-31

Completion date

2011-09-30

Last updated

2013-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

BIIB022, Stage IV, Taxol, Stage IIIB, Carboplatin, Paclitaxel, Non Small Cell Lung Cancer, Treatment Naive, Anti IGF1R, NSCLC, Open Label, IGF1R, Paraplatin, Cytotoxic, Mitotic Inhibitor, Taxane, Alkylating agent

Brief summary

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Interventions

DRUGBIIB022 With Paclitaxel and Carboplatin

Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>/= 18 years old * Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer * ECOG Performance Status 0 or 1

Exclusion criteria

* History of another primary cancer within 3 years * Any prior or concurrent investigational or standard therapy for treatment of NSCLC * Prior anti-IGF-1R therapy * Unstable diabetes

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and tolerability of BIIB022 in combination with paclitaxel and carboplatin	6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026